OR WAIT null SECS
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 02, 2024
Proprietary cell lines offer opportunities for achieving high AAV titers.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 20, 2024
FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.
February 02, 2024
Despite slow growth over recent years, the CAR-T cell therapy space is expected to see considerable advancements in the near future.
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.
February 01, 2024
The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.
January 04, 2024
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.